Molecular mechanisms for vascular complications of targeted cancer therapies

Abstract

Molecularly targeted anti-cancer therapies have revolutionized cancer treatment by improving both quality of life and survival in cancer patients. However, many of these drugs are associated with cardiovascular toxicities that are sometimes dose-limiting. Moreover, the long-term cardiovascular consequences of these drugs, some of which are used chronically, are not yet known. Although the scope and mechanisms of the cardiac toxicities are better defined, the mechanisms for vascular toxicities are only beginning to be elucidated. This review summarizes what is known about the vascular adverse events associated with three classes of novel anti-cancer therapies: vascular endothelial growth factor (VEGF) inhibitors, breakpoint cluster-Abelson (BCR-ABL) kinase inhibitors used to treat chronic myelogenous leukaemia (CML) and immunomodulatory agents (IMiDs) used in myeloma therapeutics. Three of the best described vascular toxicities are reviewed including hypertension, increased risk of acute cardiovascular ischaemic events and arteriovenous thrombosis. The available data regarding the mechanism by which each therapy causes vascular complication are summarized. When data are limited, potential mechanisms are inferred from the known effects of inhibiting each target on vascular cell function and disease. Enhanced understanding of the molecular mechanisms of vascular side effects of targeted cancer therapy is necessary to effectively manage cancer patients and to design safer targeted cancer therapies for the future.

Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial

“…In addition, functional disorders of the kidneys, liver, and thyroid are often associated with TKIs [14,15,17]. The occurrence and progression of these AEs are suggested to be mediated by complex mechanisms that involve inflammation, oxidative stress, and the immune system [19,20,21]. Based on these findings, we hypothesized that controlling these biological factors may suppress TKI-induced adverse events.…”

Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury

“…Common to these cardiovascular pathologies is endothelial dysfunction and vascular injury. Potential mechanisms implicated in VEGFi-induced hypertension include increased endothelin-1 (ET-1) levels, renin–angiotensin system activation, endothelial cell apoptosis, and microvascular rarefaction 6 , 8 , 9 . Recently, we demonstrated in in vivo and in vitro studies that vatalanib, a VEGFi, increased the generation of reactive oxygen species (ROS) in vascular cells and decreased activation of endothelial nitric oxide synthase (eNOS) and production of nitric oxide (NO) resulting in endothelial dysfunction and vascular hypercontractility in VEGFi-treated mice 10 .…”

Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles

“…VEGF is a growth factor that is essential for angiogenesis, endothelial cell permeability, and general preservation of vessel function (Gopal, et al 2016). KSP is a microtubule interacting protein that is involved in the regulation of mitosis and apoptosis (Naymagon and Abdul-Hay 2016).…”